Alunbrig Shows Promise in Certain Advanced NSCLC Patients with ALK Mutations, Study Reports
News
Takeda’s Alunbrig (brigatinib) has shown promise in treating ALK-positive metastatic non-small cell lung cancer (NSCLC) patients who either progressed with — or could not tolerate treatment with — Xalkori (crizotinib). ... Read more